The
cancer profiling market in terms of technology has been segmented into
next generation sequencing (NGS), quantitative polymerase chain reaction
(QPCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and
microarray, based on technology. NGS held the largest share in the cancer/tumor
profiling industry, standing at 33.1%, in 2016. This leading position of NGS is
mainly characterized by increased awareness about NGS products due to rising
promotional activities for these products among the research laboratories and
academic institutes. The NGS category is also expected to grow at the highest
CAGR during the forecast period.
The players in the market are developing different biomarkers based on what is to be detected in a patient. For instance, Caris Life Sciences, develops several biomarkers that are based on IHC, that detects the level of protein expression, translocations and fusions, ISH, amplifications, detects gene deletions, NGS, rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome, and fragment analysis, that detects changes in RNA or DNA to indicate the absence or presence of genetic marker. Due to this precise detection using biomarkers for the cancer-causing agent, there is an increase in the use of biomarkers for cancer profiling and thereby driving the growth of the cancer/tumor profiling market.
Europe held the second largest share of 27.7% in the global cancer/tumor profiling market in 2016. The growth in the European market for cancer/tumor profiling is mainly led by growing aging population, increasing prevalence of chronic pain, and neurological disorders and R&D infrastructure. By 2023, the European market for cancer/tumor profiling is expected to cross $23.0 billion dollar, growing at a CAGR of 18.5% between 2017-2023. Among all the European countries, Germany held the largest share in the European cancer/tumor profiling industry and is expected to register a CAGR of 19.3% in the forecast period.
The players in the market are developing different biomarkers based on what is to be detected in a patient. For instance, Caris Life Sciences, develops several biomarkers that are based on IHC, that detects the level of protein expression, translocations and fusions, ISH, amplifications, detects gene deletions, NGS, rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome, and fragment analysis, that detects changes in RNA or DNA to indicate the absence or presence of genetic marker. Due to this precise detection using biomarkers for the cancer-causing agent, there is an increase in the use of biomarkers for cancer profiling and thereby driving the growth of the cancer/tumor profiling market.
Europe held the second largest share of 27.7% in the global cancer/tumor profiling market in 2016. The growth in the European market for cancer/tumor profiling is mainly led by growing aging population, increasing prevalence of chronic pain, and neurological disorders and R&D infrastructure. By 2023, the European market for cancer/tumor profiling is expected to cross $23.0 billion dollar, growing at a CAGR of 18.5% between 2017-2023. Among all the European countries, Germany held the largest share in the European cancer/tumor profiling industry and is expected to register a CAGR of 19.3% in the forecast period.
GLOBAL CANCER PROFILING
MARKET SEGMENTATION
By Technology
·
Next generation
sequencing (NGS)
o By region
·
Quantitative polymerase
chain reaction (QPCR)
o By region
·
Immunohistochemistry
(IHC)
o By region
·
In-situ hybridization
(ISH)
o By type
§ Fluorescent in situ hybridization (FISH)
§ Chromogenic in situ hybridization (CISH)
o By region
·
Microarray
o By region
By Technique
·
Genomics
o By region
·
Proteomics
o By region
·
Epigenetics
o By region
·
Metabolomics
o By region
By Application
·
Personalized medicine
o By region
·
Diagnostics
o By region
·
Biomarker discovery
o By region
·
Prognostics
o By region
By Geography
North America
·
By technology
·
By technique
·
By application
·
By country - The U.S.
and Canada
Europe
·
By technology
·
By technique
·
By application
·
By country - Germany,
U.K., France, and Rest of Europe
Asia-Pacific
·
By technology
·
By technique
·
By application
·
By country - Japan,
China, and Rest of Asia-Pacific
Latin America (LATAM)
·
By technology
·
By technique
·
By application
·
By country - Brazil,
Mexico and Rest of LATAM
Middle East & Africa
(MEA)
·
By technology
·
By technique
·
By application
0 Comments